Medicinal and Process Chemistry


Medicinal chemistry is a fundamental discipline that lies at the foundation of the core mission of the EIDD. The mission of the Institute is to develop new therapies to address unmet infectious diseases and public health threats, and to provide a continuous flow of new and increasingly optimized therapeutic agents as required to maintain our development pipeline.

In addition, throughout the early development stages of our programs we remain dedicated to the identification of suitable back-up and 2nd generation compounds that can be brought forward in the event that early development studies identify deficiencies in the profile of our most advanced lead compounds that threaten to limit their usefulness and chance of successful development.

  • Synthetic organic chemistry is a core competence for all group leaders and researchers within the chemistry group
  • Well-equipped and staffed to carry out multi-step, chiral synthesis against stringent specifications for purity and efficiency
  • Highly divergent synthetic pathways are designed to rapidly interrogate the activity space of a given chemotype
  • Scale-up and process capabilities and expertise are in place to allow for the development of highly efficient and high yielding processes to deliver large scale products that meet desired release specification
  • Protocols and expertise are in place to manage the early stages of CMC (Chemistry, Manufacturing and Controls) development for IND enabling studies

For all of these objectives, we adopt a highly collaborative team approach both within our respective chemistry project team as well as with the numerous interdisciplinary collaborators and research functions that are intrinsic to the lead discovery and lead optimization process.

A Track Record of Success

Emory University is one of the most successful academic institutions at bringing medicinal innovation forward to the point where it can make a positive impact in a clinical setting on human health. Currently, 95% of all HIV drug cocktails contain a drug that was invented at Emory. The founder and Executive Director of the EIDD, Dennis Liotta, is an inventor of record for both FTC (Emtriva TM) and 3TC (Epivir TM), which have both been approved by the FDA to treat HIV infections as well as a number of clinically relevant antivirals including Reverset, Racivir and Elvucitabine. The EIDD was founded to carry on that track record of success and to provide the environment and capabilities necessary to bring early stage innovations forward to the stage of human testing where they can similarly address unmet medical needs and human health threats.